SOURCE: Generex Biotechnology Corporation

May 31, 2007 09:00 ET

Generex Biotechnology to Make Presentations at The Endocrine Society's 89th Annual Meeting

WORCESTER, MA--(Marketwire - May 31, 2007) - Generex Biotechnology Corporation (NASDAQ: GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it will be making five poster presentations at The Endocrine Society's 89th Annual Meeting in Toronto, Canada June 2 - 5, 2007 (www.endo-society.org).

Two of the abstracts feature the Company's proprietary confectionary Glucose RapidSpray™ product and its role in hypoglycemic control and as dietary supplement for weight control:

"Administration of Glucose Via Rapid Spray Device to Control Progression towards Hypoglycaemia," by Professor Paolo Pozzilli, University Campus Bio-Medico, Rome, Italy, with Antonio Picardi, Manon Yeganeh Khazrai, Maria Altomare, Natalia Visalli, and Elisa Cipponeri; and

"Glucose RapidSpray as an Adjunct in Dietary Programme for Body Weight Control," by Professor Paolo Pozzilli, University Campus Bio-Medico, Rome, Italy with Manon Yeganeh Khazrai, Maria Altomare, Natalia Visalli, Laura Cipolloni, and Anna Rita Maurizi.

The other three abstracts feature Generex Oral-lyn™, the Company's proprietary oral insulin spray product, including a study in juveniles:

"6-Month Safety and Efficacy of Oral Insulin Administered at Lunchtime in Juvenile Type-1 DM Subjects Receiving Basal Glargine Insulin and Pre-Breakfast and Pre-Dinner S.C. Regular Insulin," by Doctors Jaime Guevara-Aguirre, Marco Guevara-Aguirre, and Jeannette Saavedra, all of the Institute of Endocrinology IEMYR, Quito, Ecuador, together with Dr. Gerald Bernstein, the Company's Vice-President for Medical Affairs;

"Comparison Of Metabolic Control Of Pre-Prandial S.C. Regular Insulin Versus Prandial Split Doses Of An Oral Insulin In Adult Type-1 Diabetes Mellitus Subjects Receiving Basal S.C. Twice Daily Isophane Insulin (NPH)," by Doctors Jaime Guevara-Aguirre, Marco Guevara-Aguirre, and Jeannette Saavedra, all of the Institute of Endocrinology IEMYR, Quito, Ecuador; and

"Near Normalization of Parameters of Metabolic Control in Type-1 DM Using Conventional Insulin Therapy (CIT) and a 13-Point Method Designed to Enhance Compliance," by Doctors Jaime Guevara-Aguirre, Marco Guevara-Aguirre, and Jeannette Saavedra, all of the Institute of Endocrinology IEMYR, Quito, Ecuador, together with Dr. Gerald Bernstein, the Company's Vice-President for Medical Affairs.

The mission of The Endocrine Society is to advance excellence in endocrinology and promote its essential role as an integrative force in scientific research and medical practice. Society members represent the full range of disciplines associated with endocrinologists: clinicians, researchers, educators, fellows and students, industry professionals and health professionals who are involved in the field of endocrinology. These professionals are dedicated to the research and treatment of the full range of endocrine disorders: diabetes, reproduction, infertility, osteoporosis, thyroid disease, obesity/lipids, growth hormone, pituitary tumors, and adrenal insufficiency. The Endocrine Society works to foster a greater understanding of endocrinology amongst the general public and practitioners of complementary medical disciplines and to promote the interests of all endocrinologists at the national scientific research and health policy levels of government.

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, oral insulin (Generex Oral-lyn™), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. For more information, visit the Generex website at www.generex.com.

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Contact Information

  • For more information, please contact:

    For Generex:
    Shayne Gilliatt
    Generex
    800-391-6755 or 416-364-2551

    Andrew Hellman
    CEOcast, Inc.
    212-732-4300